- CEO
- Yong Deng
- Full Time Employees
- 461
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Changdu China
- IPO Date
- Sep 29, 2021
- Business
- Tibet Duo Rui Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise engaged in the research, development, manufacturing, and commercialization of chemical pharmaceutical preparations, active pharmaceutical ingredients (APIs), chemical intermediates, and traditional Chinese medicine formulations. The company operates primarily across pharmaceutical manufacturing and biotechnology segments, serving hospitals, medical centers, and life sciences clients across domestic and international markets. Its commercial and development product portfolio is categorized into: parenteral solutions and fluid balance therapies, featuring its flagship sodium acetate Ringer's injection for electrolyte regulation and acidosis correction, compound electrolyte injections, and compound mannitol injections; specialized clinical formulations for intensive care, anesthesia, and analgesia; peptide active pharmaceutical ingredients and therapeutic peptides, including lanreotide acetate, semaglutide, teriparatide, and tirzepatide; proprietary Chinese medicine formulations, including Yifei Jisheng granules; and contract development and manufacturing organization (CDMO) as well as custom synthesis services for biopharmaceutical developers. Founded in 2016 and headquartered in Qamdo, Tibet Autonomous Region, China, the company maintains research, administrative, and manufacturing facilities across regional centers in China, including advanced peptide API synthesis and formulation facilities in Sichuan Province. In recent strategic developments, the company expanded its upstream biotechnology value chain through the acquisition of Sichuan Frontier Biopharmaceutical Co., Ltd. (rebranded as Sichuan Duorui Pharmaceutical Co., Ltd.), establishing a high-end peptide API development and industrialization base focused on metabolic and therapeutic peptide pipelines. Additionally, the company completed a major ownership and management transition resulting in a change of actual control to a leadership consortium comprising Wang Qingtai, Cui Zihao, and Cao Xiaobing to drive operational modernization, alongside an internal asset optimization program that included the divestment and restructuring of non-core subsidiary assets such as Hubei Duorui Pharmaceutical Co., Ltd. to focus resources on core formulation competitiveness and advanced peptide API manufacturing.